Cancer Gene Therapy Market Size, Share and Growth Outlook, 2026

Cancer Gene Therapy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cancer Gene Therapy Market size is forecast to increase from $8 Billion in 2026 to $28.48 Billion in 2034 at a CAGR of 17.2% between 2026 and 2034.

The Cancer Gene Therapy market report provides detailed analysis and outlook of Cancer Gene Therapy segments including By Therapy Modality (Gene-Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer, CRISPR-Based Gene-Editing Therapies, RNAi-Based Gene-Silencing Therapies), By Vector Type (Viral Vectors, Non-Viral Vectors ), By Cancer Type (Hematologic Malignancies, Solid Tumors ), By Manufacturing Source (In-House Facilities, Contract Development & Manufacturing Organizations ), By End-User (Hospitals and Specialized Cancer Centers, Biotechnology and Pharmaceutical Companies, Academic and Government Research Laboratories) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cancer Gene Therapy Industry Overview

Regulatory Frameworks Accelerating Gene Therapy Development

The cancer gene therapy industry is benefiting from expanding regulatory support designed to streamline development pathways for advanced genetic medicines. The U.S. Food and Drug Administration finalized updated compliance frameworks, including detailed guidance for the development of Chimeric Antigen Receptor (CAR) T-cell products. These recommendations provide clearer manufacturing expectations for ex vivo viral gene transfer processes, helping developers establish robust potency standards, optimize dose selection strategies, and advance investigational therapies efficiently through Investigational New Drug (IND) programs. Regulatory clarity is particularly important for gene therapy developers seeking to commercialize increasingly complex cellular and genetic platforms. The evolving framework reflects growing confidence in gene-modified therapies as an important component of modern oncology treatment strategies and supports continued innovation across the cancer gene therapy landscape.

CAR-T Cell Therapies Advancing Hematologic Cancer Treatment

Adoption of genetically engineered cellular therapies continues to expand within the cancer gene therapy industry. Autolus Limited strengthened its operational capabilities following the inclusion of AUCATZYL (obecabtagene autoleucel) on the FDA-approved biologics registry. The therapy is a CD19-directed autologous CAR-T treatment engineered with a specialized fast-off binding kinetic mechanism that enhances cellular targeting while reducing the risk of severe cytokine release syndrome. Designed for adult leukemia indications, the therapy exemplifies ongoing efforts to improve both efficacy and safety within the CAR-T segment. Advances in genetic engineering, cell processing, and manufacturing technologies are enabling developers to refine therapeutic performance while addressing historical limitations associated with immune-related toxicities and treatment scalability.

AAV-Based Gene Therapies Expanding Oncology and Rare Disease Applications

Adeno-associated virus (AAV)-based gene therapies are becoming increasingly prominent across the broader gene therapy ecosystem, including applications with relevance to oncology and immune modulation. Siren Biotechnology received FDA Fast Track designation for SRN-101, an AAV-based immuno-gene therapy designed to treat recurrent high-grade glioma. The therapy delivers an engineered cytokine directly into tumors to stimulate localized anti-tumor immune responses and is advancing toward first-in-human clinical evaluation. Simultaneously, broader gene therapy innovation continues to strengthen industry infrastructure. Ultragenyx secured FDA acceptance and Priority Review for its Biologics License Application for DTX401, an AAV-based therapy developed for Glycogen Storage Disease Type Ia, supported by Phase 3 data demonstrating improved metabolic control and reduced cornstarch dependence. In parallel, Neurogene received Breakthrough Therapy designation for NGN-401, a gene therapy candidate for Rett syndrome currently progressing through the registrational Embolden trial. These regulatory milestones demonstrate increasing confidence in viral vector-based platforms and the expanding capabilities of gene transfer technologies that are also being adapted to support future cancer gene therapy innovations, targeted immune modulation strategies, and precision genetic medicine approaches.

Cancer Gene Therapy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cancer Gene Therapy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Amgen Inc., Bristol-Myers Squibb Company (Celgene), Bluebird Bio Inc., Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Adaptimmune Therapeutics plc, Merck KGaA, GlaxoSmithKline plc (GSK), ElevateBio LLC, Shanghai Sunway Biotech Co., Ltd.. The Cancer Gene Therapy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cancer Gene Therapy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cancer Gene Therapy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cancer Gene Therapy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cancer Gene Therapy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cancer Gene Therapy Market Competitive Benchmarking and Company Analysis

Leading companies in Cancer Gene Therapy industry include- Amgen Inc., Bristol-Myers Squibb Company (Celgene), Bluebird Bio Inc., Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Adaptimmune Therapeutics plc, Merck KGaA, GlaxoSmithKline plc (GSK), ElevateBio LLC, Shanghai Sunway Biotech Co., Ltd.. The Cancer Gene Therapy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cancer Gene Therapy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cancer Gene Therapy market remains one of the strongest-performing segments in the country.
The US Cancer Gene Therapy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cancer Gene Therapy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cancer Gene Therapy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cancer Gene Therapy markets

Canada's strong Cancer Gene Therapy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cancer Gene Therapy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cancer Gene Therapy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cancer Gene Therapy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cancer Gene Therapy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cancer Gene Therapy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cancer Gene Therapy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cancer Gene Therapy sales through 2034

France Cancer Gene Therapy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cancer Gene Therapy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cancer Gene Therapy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cancer Gene Therapy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cancer Gene Therapy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cancer Gene Therapy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cancer Gene Therapy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cancer Gene Therapy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cancer Gene Therapy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cancer Gene Therapy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cancer Gene Therapy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cancer Gene Therapy Market Segmentation

By Therapy Modality
Gene-Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
CRISPR-Based Gene-Editing Therapies
RNAi-Based Gene-Silencing Therapies
By Vector Type
Viral Vectors
Non-Viral Vectors
By Cancer Type
Hematologic Malignancies
Solid Tumors
By Manufacturing Source
In-House Facilities
Contract Development & Manufacturing Organizations
By End-User
Hospitals and Specialized Cancer Centers
Biotechnology and Pharmaceutical Companies
Academic and Government Research Laboratories

Top Companies in Cancer Gene Therapy Industry

Amgen Inc.
Bristol-Myers Squibb Company (Celgene)
Bluebird Bio Inc.
Novartis AG
Gilead Sciences, Inc. (Kite Pharma)
Adaptimmune Therapeutics plc
Merck KGaA
GlaxoSmithKline plc (GSK)
ElevateBio LLC
Shanghai Sunway Biotech Co., Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa